Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Wisconsin, Madison
With
Progen Pharmaceuticals
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Metastatic hormone refractory prostate cancer.
Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1.
testosterone \<50ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.
Progressive disease after androgen deprivation.
You may not be if
Patients whose clinical condition would make chemotherapy clearly indicated.
Patients who have received systemic chemotherapy for the treatment of metastatic disease.
Peripheral neuropathy \> Grade 1
Prior anti-angiogenic therapy, including thalidomide.
Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry.
Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.
Patients with known brain metastases or history of brain metastases.
History of stroke within 6 months of treatment or other significant neurological limitations.
Patients who have received more than 2 prior investigational treatments.
Uncontrolled intercurrent illness
Patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias
Clareo Health | Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
